TY - JOUR T1 - Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort JF - Gut Y1 - 2016 A1 - T M Welzel A1 - Petersen, J. A1 - Herzer, K. A1 - et, al VL - 65 SP - 1861-1870 IS - 11 ER -